OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
| Autor: | Cho, B.C., Camidge, D.R., Lin, J.J., Kim, S.-W., Solomon, B., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A.J., Wolf, J., Lee, K.H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Lu, S., Kao, S., Velcheti, V., Cheema, P., Stopatschinskaja, S., Mehta, M., Trone, D., Ades, F., Calvet, C.Y., Drilon, A. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; November 2023, Vol. 18 Issue: 11, Number 11 Supplement 1 pS50-S51, 2p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|